SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019).
Diagnosis
Gastric cancer
Gastroesophageal junction adenocarcinoma
Treatment
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
30
11
2019
accepted:
30
11
2019
pubmed:
29
1
2020
medline:
31
10
2020
entrez:
29
1
2020
Statut:
ppublish
Résumé
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.
Identifiants
pubmed: 31989475
doi: 10.1007/s12094-019-02259-9
pii: 10.1007/s12094-019-02259-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-244Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Cancer. 2012 Nov 15;118(22):5481-8
pubmed: 22549558
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
J Clin Oncol. 2010 Dec 10;28(35):5210-8
pubmed: 21060024
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
J Clin Oncol. 2012 Jul 1;30(19):2327-33
pubmed: 22585691
Ecancermedicalscience. 2018 Nov 26;12:883
pubmed: 30679950
Br J Cancer. 2017 Jun 6;116(12):1526-1535
pubmed: 28463962
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
J Clin Oncol. 2015 Oct 1;33(28):3130-6
pubmed: 25559811
Gastroenterology. 2013 Sep;145(3):554-65
pubmed: 23684942
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
Surg Clin North Am. 2017 Apr;97(2):317-331
pubmed: 28325189
J Gastroenterol. 2019 Aug;54(8):669-673
pubmed: 31172291
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
J Clin Oncol. 2009 Feb 20;27(6):851-6
pubmed: 19139439
JAMA. 2010 May 5;303(17):1729-37
pubmed: 20442389
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
Ann Surg Oncol. 2014 Jun;21(6):2005-11
pubmed: 24526547
J Surg Oncol. 2013 Jun;107(8):807-14
pubmed: 23512524
Biomed Pharmacother. 2018 Jul;103:1688-1700
pubmed: 29864959
Gastric Cancer. 2012 Sep;15 Suppl 1:S19-26
pubmed: 22237654
Br J Cancer. 2017 Sep 5;117(6):775-782
pubmed: 28765618
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686